Genotype and Intensive Pretreatment Influence Outcome of Acute Myeloid Leukemia Patients Treated With Venetoclax in Combination With Hypomethylating Agents or Low-dose Cytarabine: "Real World" Data From Germany

Hemasphere. 2022 Aug 9;6(9):e759. doi: 10.1097/HS9.0000000000000759. eCollection 2022 Sep.

Krischan Braitsch¹, Laura K Schmalbrock^{2

3}, Paul Jung², Irmgard Bumeder⁴, Philipp Kiewe⁵, Judith S Hecker¹, Mareike Verbeek¹, Jörg Westermann⁶, Lars Bullinger^{3

6

7}, Ulrich Keller^{2

7}, Florian Bassermann^{1

7

8}, Jan Krönke², Katharina S Götze^{1

7

8}, Kathrin Rieger²

¹ Department of Medicine III, Technical University Munich, Klinikum Rechts der Isar, Munich, Germany.
² Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany.
³ Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Germany.
⁴ Praxis und Tagesklinik für Hämatologie und internistische Onkologie, Munich, Germany.
⁵ Onkologischer Schwerpunkt am Oskar-Helene-Heim, Berlin, Germany.
⁶ Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany.
⁷ German Cancer Consortium (DKTK), Partner Sites Berlin/Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany.
⁸ Bavarian Cancer Research Center (BZKF), Partner Site Munich, Germany.

No abstract available